Taking too long? Close loading screen.
Connect with us


SPACs, explained



I keep hearing about these SPAC things. First of all, what are they, and second of all, why?

“SPAC” stands for special-purpose acquisition company, which is kind of an obtuse way of saying “a mountain of cash that exists for a merger”; it is also sometimes called a “blank-check” company, usually in articles like this one that explain what SPACs are. You’re hearing about them because there were 112 SPAC IPOs. The Wall Street Journal has dubbed 2020 a record year for SPACs.

SPACs aren’t really new, though they’ve only existed in their current form since 2003, according to Milos Vulanovic, a professor at EDHEC Business School who’s studied SPACs for years. The problem in the 1980s and 1990s was, um, pump-and-dump schemes. But a bunch of laws have changed since then, and you are hearing about them more often now because some companies are turning to SPAC acquisition in lieu of a traditional initial public offering.

What’s wrong with a traditional IPO?

Well, it’s kind of a pain in the ass. There’s the roadshow, where you try to get investors interested, and there’s uncertainty around your valuation until pretty close to the offering. You’re also negotiating with multiple investors, usually institutional investors, which is complex and annoying. Plus, uncertainty can tank your IPO — remember WeWork? The company expected to raise, like, $4 billion with an IPO. Instead, people staged dramatic readings of its S-1 as comedy routines, and the IPO was canceled.

Anyway, there seems to be more uncertainty now than there was last year. There’s been this pandemic thing that has made markets a little weirder than usual. There’s a presidential election coming up. If I’m running a unicorn, and I need to raise money, maybe the IPO doesn’t look as good as it used to. Maybe I want something easier — or less risky.

With a SPAC, the IPO is already done. All you’re doing is negotiating with one party: the SPAC that might acquire you. That means you already know the valuation, you don’t have to do a roadshow, and you can cash out your existing investors. Plus, the whole process is a lot faster because you’re only negotiating with one party! “When you compare it to an IPO, the pitch is actually very simple: it is a better way to go public,” Chinh Chu, an influential SPAC sponsor, told Bloomberg News. He noted that IPOs are subject to the vagaries of the market; SPACs aren’t.

SPACs are another way for companies to get late-stage growth capital, says David Erickson, the former co-head of global equity capital markets at Barclays, who now is a lecturer of finance at Wharton School of Business at the University of Pennsylvania. “If you’re acquired, you want something out of it,” Erickson says.

Also, depending on the sponsor, you may get to incorporate people who are smart and good at running public companies into board seats or whatever. So it’s got some merger characteristics, which makes sense since, you know, there’s an acquisition involved.

What’s the downside to going public through a SPAC?

Aside from the sponsor, you might not get long-term investors since the people who’ve invested in SPACs have different goals than a normal investor; for starters, they might not know or care about your company until it’s time to acquire it.

Also, they’re more expensive than an IPO, writes Matt Levine, a columnist at Bloomberg. In order to do an IPO, you wind up paying investment banks 1 percent to 7 percent of what you raise; in a SPAC, the underwriter gets 5.5 percent and there may be other fees associated with the merger — you have to pay a bank to consult on the deal, for instance. “So SPAC fees are about a quarter of the money raised, three or four times as much as you’d pay in an IPO, albeit better disguised,” Levine writes.

Plus, in most cases, the sponsor gets 20 percent of the stock for cheap.

Some investors may be wary of buying shares of a company that went public through a SPAC because the amount of due diligence required for a merger may be less than what the Securities and Exchange Commission requires for a regular IPO. “There’s less scrutiny of the existing business,” says John Howe, a professor of finance at the University of Missouri. “The due diligence is done by Bill Ackman or someone.”

Bill Ackman?

The billionaire founder of Pershing Square Capital Management who tried to buy Airbnb with his SPAC. He’s one of a bunch of people who have formed the shell companies that do the acquisitions. They’re usually led by a famous investor, in fact, and a quick trip through the who’s who of SPACs might convince you that forming a SPAC has replaced golfing.

In the last four or five years, the quality of SPAC management teams has drastically improved, says Erickson. “SPAC sponsors have gotten a lot better,” he says.

Here is an incomplete list of SPAC sponsors:

For the purposes of the tech world, though, the most influential SPAC booster is probably Chamath Palihapitiya, the founder of Social Capital. He created the SPAC that bought Virgin Galactic and also the SPAC that bought Opendoor. Now, Palihapitiya, a former Facebook exec, has three more SPACs in the works.

Wait, why are all of these people sponsoring SPACs?

Finance people notoriously love money, so I’m guessing that has something to do with it.

Beyond that, I have a guess. Silicon Valley is bloated with “unicorns,” companies with valuations of more than $1 billion, valuations that are that high because many of these companies stayed private longer than startups used to. It’s possible that someone clever has figured out that there are a bunch of companies overdue for going public and has decided that this method will make money for them rather than the banks who traditionally handle IPOs.

Can you explain to me what is going on with these shell companies the famous investors make, using Metallica references?

Does Lars hate Napster? Let’s say I am a famous and fancy investor, the founder of Ride the Lightning Capital. I decide it’s a smart idea for me to create a SPAC because, in my specific case, risk makes me feel alive.

So the first thing I do is put together an investor roadshow for my SPAC IPO and trot off to convince people to join my SPAC as investors. As part of my pitch, I might say that I am looking for “mature unicorns,” or I might just leave it open-ended. Usually, SPACs are priced at $10 for a share and a warrant or fraction of a warrant, which is a document that gives a person the right to buy a share at a specific price after the merger. So if you bought into my SPAC, you get a share and the possibility of buying more.

Anyway, I raise a bunch of money for my IPO, which is procedurally simple, because there’s no business to review; it’s an “IPO about nothing,” Barron’s wrote in 2005. Once my SPAC, For Whom the Bell Tolls ($BELL), successfully IPOs, I then set about finding a business to acquire. I have a deadline, usually 18 months. While I’m looking for my mature unicorn or possibly a pegasus or maybe the four horsemen, most of the sweet gobs of money I raised from my investors are put in escrow. If I don’t find myself a company to buy, I have to give all that money back, minus maybe some fees.

But let’s say I find a business I like: Load, a laundry-focused startup that aims to disrupt the traditional laundromat. When I sign my purchase agreement, all the investors in For Whom the Bell Tolls will either vote or engage in a tender offer; the outcome is roughly the same. In either case, my investors from the roadshow can either return their shares to me (in which case, I give them most or all of their money back) or they are now the proud owners of Load, a brand-new public company.

It’s worth pointing out this is a pretty good deal for the investors! Participating in the SPAC is low-risk. If an investor doesn’t like the target company I pick, they can simply get their money back. Plus, they can trade their shares or the warrants. This is the kind of thing that hedge fund people — who love complex financial engineering — get really excited about, though hedgies aren’t the only people who invest in SPACs.

Oh, is laundry a hot sector for SPAC acquisition?

Well, no, I just thought that was a funny example. This year, the big boom is electric vehicle companies, according to Kristi Marvin, the founder of SPACInsider. “I’ve been calling 2020 the year of ‘deals with wheels’ for SPACs,” she said in an email. EV companies, including Lordstown Motors, Nikola, XL Fleet, Canoo, and Fisker — as well as EV powertrain company Hyliion and EV battery company QuantumScape — have either agreed to be acquired by a SPAC or have been acquired already.

She points out that tech has also been a hot area for deals that have recently been announced, such as Porch, Opendoor, and Shift. There also have been gaming deals, such as Golden Nugget, DraftKings, and Rush Street.

Several SPACs have gone public without yet making an acquisition. Among those, biotech and health care are hot now, according to Marvin.

What’s the deal with Nikola?

Oh yeah, that’s fun. So… if the SPAC boom ends soon, my guess is that Nikola will have had something to do with it. I mentioned this earlier, but one drawback to SPACs — maybe! — is that someone aside from the SEC does due diligence, and this is where Nikola gets interesting. It went public on June 4th by merging with former GM chairman Steve Girsky’s VectoIQ. According to its SEC documents from 2018, VectoIQ had 24 months to make an acquisition or Girsky was going to have to give his investors their money back; the company listed on the Nasdaq in May. You don’t have to be very good at math to figure out the 2020 acquisition was near the end of that window.

So anyway, VectoIQ effectively makes Nikola a public company by buying it, and at first, everything looks rosy — the share price spikes to $93.99, more than double its value. “At one point Nikola had a market capitalization above Ford’s, despite the fact that the electric vehicle maker said it would not generate revenue until 2021,” CNBC informs us. CNBC also notes that the stock was popular on Robinhood, an app that allows free stock trades. GM takes a stake in the company, in exchange for in-kind services, on September 8th — exactly the kind of thing that makes an investor with Girsky’s connections a good deal for a company that goes public through a SPAC.

Then, on September 10th, short-seller Hindenburg Capital releases an absolute motherfucker of a report. (Its title is “Nikola: How to Parlay An Ocean of Lies Into a Partnership With the Largest Auto OEM in America.”) In places, the report echoes a June Bloomberg story that suggests Nikola’s founder, Trevor Milton, exaggerated the company’s capabilities in a video demo of a Nikola semi truck. Anyway, Milton stepped down on September 21st, just before a Financial Times report said Milton didn’t create Nikola’s designs — he bought them.

Girsky and GM CEO Mary Barra say they did due diligence on the company. “We showed up with an army of people to due diligence this thing,” Girsky said on August 2nd. That hasn’t stopped some investors from raising eyebrows. “There is obviously someone on the diligence side who isn’t going to get a nice bonus this year,” Reilly Brennan, founder of VC fund Trucks Inc, told Bloomberg.

Anyway, the SEC is investigating now, so I suppose we will all find out exactly how good the due diligence was. The entire spicy episode has underlined the concerns about due diligence in SPACs, though I suppose it’s possible that if the SEC gives Nikola a clean bill of health, everyone will forget this happened, and the SPACs will continue to bloom.

Is that normal in companies that go public through SPACs?

Well, the American Bar Association has suggested that there’s going to be an uptick in SPAC-related lawsuits, so that’s not what I would call a good sign. But as the ABA itself points out, lawsuits are going to be more likely as SPACs become more popular — regardless of the suits’ merit.

Still, SPACs have a bad reputation when it comes to fraud. For instance, a Greek streaming company, Akazoo, was listed on the markets in 2019. A short-seller named Gabriel Grego did some digging and determined that the subscriber numbers Akazoo gave couldn’t possibly be right. The company’s board launched an investigation, “eventually concluding that the company’s previous management had ‘participated in a sophisticated scheme to falsify Akazoo’s books and records,’” including the documents that had been given to the acquiring SPAC, according to the Financial Times.

Usually, though, the risks are less extreme than that. In 2015 and 2016, 33 SPACs did IPOs, The Wall Street Journal reported. Of these, 27 did mergers. By 2019, 20 of these companies traded below their IPO price. According to that story, between 2010 and 2017, SPACs performed about 3 percent more poorly than the broader market, though some of that may be due to the escrow accounts used to park the pre-merger cash: interest rates were low while the market was frothy.

A similar analysis from the Financial Times of the SPACs from 2015 and 2019 found the majority trade below their original price of $10 a share.

This seems like another way for Wall Street to make a lot of profit at retail investors’ expense!

That’s more of a comment than a question, but I’ll respond to it anyway. The only book you need to read to understand Wall Street is Fred Schwed’s Where are the Customers’ Yachts? Banks make big-boy money on fees. Any kind. Underwriting a SPAC’s IPO, consulting on the eventual merger…

When will the SPAC boom end?

Hard to say! There are a lot of things that could shut this down — investors getting cold feet, more companies like Airbnb declining to be acquired, regulatory action — but looking at the past, SPACs usually cool off in a bear market, says Howe.

How soon do you think we’ll be in a bear market?

If I knew that kind of thing, do you think I’d be a professional internet typist? Anyway, to tide you over in the meantime, here are some fat bears.


Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *


Facebook reportedly bracing for US election chaos with tools designed for “at-risk” countries



Facebook is planning for possible chaos around the November 3rd US presidential election with internal tools it’s used before in countries like Sri Lanka and Myanmar, The Wall Street Journal reported.

The plans may include slowing the spread of posts as they begin to go viral, altering the news feed algorithm to change what content users see, and changing the rules for what kind of content is dangerous and warrants removal. They’re strategies Facebook has previously used in so-called “at-risk” countries dealing with mass ethnic unrest or political bloodshed.

The tools would only be used in the event of election-related violence or other serious circumstances, according to the WSJ, but some employees at the company said they were concerned that attempting to slow down viral content could unintentionally hide legitimate political discussions.

Facebook’s handling of violent hate speech against Rohingya Muslims in Myanmar several years ago was widely criticized. After a 2018 independent assessment of the situation, the social media giant conceded it wasn’t “doing enough to help prevent our platform from being used to foment division and incite offline violence. We agree that we can and should do more.” It pledged to better prepare for future risks.

Facebook CEO Mark Zuckerberg said in a September blog post that the US presidential election “is not going to be business as usual.” He said he was “worried that with our nation so divided and election results potentially taking days or weeks to be finalized, there could be an increased risk of civil unrest across the country.”

Platforms are bracing for pre-and post-election uncertainty in the US, after President Trump has repeatedly criticized mail-in voting, which many people are using this election cycle due to the coronavirus pandemic. He’s also declined to say whether he would accept the election results if he loses.

Facebook said last month that it would not accept new political ads a week before the US election (but those that had already been approved will continue running). It also added a “voter information center” at the top of Facebook and Instagram feeds, and plans to provide live, official election results when available via a partnership with Reuters. Facebook has said it will label any posts declaring premature victory, and will remove posts with misinformation about COVID-19 and voting. And it plans to ban all US political ads indefinitely after the November 3rd election.


Continue Reading


Upgrade Your PC Gaming Setup Today With a New Respawn Desk ($63 Off) And Gigabyte G27F Monitor ($40 Off)



Respawn 1010 Gaming Desk in Red | $150 | Newegg

Gigabyte G27F 27-in. Gaming Monitor | $210 | Newegg | Promo code 93XPW42

This Gigabyte G27F 27-inch gaming monitor has a 144Hz refresh rate and a 1 millisecond response time, as well as a 1920 x 1080 IPS display. You can get it for $40 off, bringing it down to $210, when you apply promo code 93XPW42 at checkout.


Why not grab a new Respawn 1010 gaming desk to put your spanking new monitor on? It’s $63 off and can also be found on Newegg. Both of these deals are good for today only, and they also both ship for free.



Continue Reading


The US now seems to be pinning all of its hopes on COVID-19 therapies and vaccines



Almost eight months after the White House first announced it would move from containment to mitigation efforts to stop the spread of the COVID-19 epidemic, the Administration is now pinning its hopes on vaccines to inoculate the population and therapies to treat the disease.

Months after announcing it would be working with technology giants Apple and Google on a contact tracing app (and nearly two months after Google and Apple rolled out their exposure notification features) and initiating wide spread testing efforts nationwide with the largest national pharmacies (which never received the coordinated support it needed),  the Administration appears to be giving up on a national effort to stop the spread of the COVID-19 epidemic.

In an interview with CNN’s Jake Tapper White House Chief of Staff Mark Meadows said that the US is “not going to control the pandemic… We are gonna control the fact that we get vaccines, therapeutics and other mitigation.”

The admission is a final nail in the coffin for a federal response that could have involved a return to lockdowns to stop the spread of the virus, or national testing and contact tracing and other mitigation measures. Meadows statement comes as the US experiences a second peak in infection rates. There are now over 8.1 million cases and over 220,000 deaths since the first confirmed infection on US soil on January 20. 

Now, the focus is all on the vaccines, therapies and treatments being developed by large pharma companies and startups alike that are making their way through the approval processes of regulatory agencies around the world.

The vaccines in phase three clinical trials

There are currently 12 vaccines in large scale, late-stage clinical trials around the world, including ones from American companies Novavax, Johnson & Johnson, Moderna Therapeutics, and Pfizer who are recruiting tens of thousands of people in the US and UK to volunteer for testing.

In China, the state run pharmaceutical company Sinopharm has filed its application to China’s regulatory commission for the approval of a vaccine and hundreds of thousands of civilians have already been vaccinated under emergency use approvals from the Chinese government, according to a report in the New Yorker. Meanwhile the privately held Chinese pharmaceutical company, Sinovac, is moving forward with phase three trials for its own vaccine in Brazil, Bangladesh and Indonesia. Another private Chinese company, CanSino Biologics developed a vaccine that was already being distributed to members of the Chinese military in late July,

A collaboration in the U.K. between the University of Oxford and European pharmaceutical company AstraZeneca is also recruiting volunteers in Brazil, India, the United Kingdom, the US and South Africa. And, in Australia, the Murdoch Children’s Research Institute is trying to see whether a vaccine used to prevent tuberculosis could be used to vaccinate against the coronavirus.

Finally in Russia, the Gamaleya National Center of Epidemiology and Microbiology in partnership with the state-run Russian Direct Investment Fund have claimed to have developed a vaccine that the country has registered as the first one on the market cleared for widespread use. Russia has not published any data from the clinical trials it claims to have conducted to prove the efficacy of the vaccine and the World Health Organization still considers the treatment to be in the first phase of development.

Therapies in phase three clinical trials

If vaccines can prevent against infection, a slew of companies are also working on ways to limit the severity of the disease should someone become infected with Sars-Cov-2, the novel coronavirus that causes COVID-19.

The Milken Institute lists 41 different therapies that have made it through to phase three of their clinical trials (the last phase before approval for widespread delivery).

These therapies come in one of five primary categories: antibody therapies, antivirals, cell-based therapies, RNA-based treatments, and repurposing existing treatments that may be in pharmaceutical purgatory.

Antibody therapies use the body’s natural defense systems either taken from the blood of people who have recovered from an infection or manufactured in a lab to neutralize the spread of a virus or bacteria. Antivirals, by contrast, stop a virus from spreading by attacking the viruses’ ability to replicate. Cell-based therapies are designed to boost the immune system’s ability to fight pathogens like viruses or bacteria. Meanwhile RNA-based treatments are another method to stop the virus from replicating by blocking the construction of viral proteins. Finally, several companies are mining their libraries of old drug compounds to see if any might be candidates for COVID-19 treatments.

So far, only three therapeutics have been approved to treat COVID-19. In the U.K. and Japan dexamethasone has received approvals, while favilavir is being used in China, Italy and Russia; and — famously thanks to its use by the President — remdesivir has been approved in the United States, Japan and Australia.

The US is also using convalescent plasma to treat hospitalized patients under emergency use authorizations. And special cases, like the President’s, have had access to other experimental treatments like Regeneron’s cell therapy under emergency use authorizations.

And there are several US-based startups developing potential COVID-19 therapies in each of these areas.

Adaptive Biotechnologies, Cytovia Therapeutics, and SAB Biotherapeutics are all developing antibody treatments. Applied Therapeutics is using an understanding of existing compounds to develop treatments for specific conditions associated with COVID-19. Cellularity has a cell-therapy that could reduce a patient’s viral load by stimulating so-called natural killer cells to attack infected cells. Humanigen has developed a new drug that could reduce fatalities in high-risk COVID-19 patients with severe pneumonia. Meanwhile Partner Therapeutics is working on a drug that could improve lung function in COVID-19 patients — and potentially boost antibody production against the virus and restore damaged lung cells. Finally, Sarepta Therapeutics has been working with the United States Army Medical Research Institute of Infectious Diseases to find ways for its RNA-based treatment to stop the spread of coronaviruses by attacking the ability for the virus to replicate.

Beyond therapies, startups are finding other ways to play a role in helping the nation address the COVID-19 epidemic.

“At this point the U.S. doesn’t have the best public health system, but at the same time we have best-in-class private companies who can sometimes operate a lot more efficiently than governments can,” Carbon Health chief executive Eran Bali told the audience at TechCrunch’s Disrupt 2020 conference. “We also just recently launched a program to help COVID-positive patients get back to health quickly, a rehabilitation program. Because as you know even if you survive it doesn’t mean your body was not affected, there are permanent effects.”

Indeed the drive for more effective at-home tests and remote treatments for consumers are arguably more important when the federal government refuses to make the prevention of viral spread a priority, because consumers may voluntarily lock down if the government won’t.

“This is an opportunity to take a technology that naturally is all about detecting viruses — that’s what CRISPR does in [its native environment] bacteria — and repurposing it to use it as a rapid diagnostic for coronavirus,” said the Nobel Prize-winning co-inventor of some foundational CRISPR gene-editing technology, Jennifer Doudna. “We’re finding in the laboratory that that means that you can get a signal faster, and you can also get a signal that is more directly correlated to the level of the virus.”


Continue Reading